Pfizer is aiming to have its COVID-19 vaccine ready for children under 12 by September, the company announced Tuesday — as it begins its next stage of testing on that age group.
Currently, children as young as 12 are able to receive the Pfizer jab in the United States, Europe and Canada.
The company’s second phase of trials on children under 12 will include 4,500 participants who will receive a higher dose of the vaccine than those in phase 1.
Children between 5 and 11 will receive a 10 microgram dose, while those aged 6 months to 5 will get 3 micrograms.
By comparison, adults and children as young as 12 are vaccinated with 30 micrograms of the drug.
A Pfizer spokesperson told Reuters that they expect to have results for 5- to 11-year-olds by September. Later that month, the company will seek emergency use authorization from regulators for that age group.
Data for the children under 5 are expected to roll in shortly after.
With Post wires